Therapeutic interventions-at study interview (approximately 1 year after the index event)
| CHD outpatient sample overall | History of stable CCS | History of ACS | P value | |
| n=721 | n=322 | n=399 | ||
| Blood pressure-lowering medications | ||||
| Use of blood pressure-lowering drugs, n (%) | 449 (62.3) | 199 (61.8) | 250 (62.7) | 0.978 |
| Beta blocker, n (%) | 488 (67.7) | 207 (64.3) | 281 (70.4) | 0.146 |
| ACEi, n (%) | 317 (45.9) | 115 (37.8) | 202 (52.2) | <0.001 |
| ARB, n (%) | 102 (14.1) | 38 (11.8) | 64 (16.0) | 0.058 |
| CCB, n (%) | 110 (15.3) | 46 (14.3) | 64 (16.0) | 0.151 |
| Diuretics, n (%) | 74 (10.3) | 32 (9.94) | 42 (10.5) | 0.223 |
| Antiplatelets | ||||
| Use of aspirin or other antiplatelets, n (%) | 673 (93.3) | 296 (91.9) | 377 (94.5) | 0.377 |
| Lipid-lowering drugs | ||||
| Statins, n (%) | 576 (79.9) | 239 (74.2) | 337 (84.5) | 0.004 |
| High intensity statin, n (%) | 421 (58.4) | 144 (44.7) | 277 (69.4) | <0.001 |
| Fibrates, n (%) | 2 (0.28) | 1 (0.31) | 1 (0.25) | 0.037 |
| Combination, n (%) | 18 (2.50) | 8 (2.48) | 10 (2.51) | 0.011 |
| Smoking cessation therapies | ||||
| Attendance at smoking cessation clinic, n (%) | 22 (3.05) | 4 (1.24) | 18 (4.51) | 0.006 |
| Nicotine replacement therapy, n (%) | 56 (7.77) | 17 (5.28) | 39 (9.77) | 0.011 |
| Bupropion, n (%) | 3 (0.42) | 0 (0.00) | 3 (0.75) | 0.03 |
| Varenicline, n (%) | 3 (0.42) | 1 (0.31) | 2 (0.50) | 0.103 |
| Influenza vaccination, n (%) | 388 (53.8) | 179 (55.6) | 209 (52.4) | 0.689 |
ACEi, angiotensin converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CCS, chronic coronary syndrome; CHD, coronary heart disease.